-

Bruker Acquires Electron Microscopy Company Nion

High-end STEM Technology Expands Bruker’s Portfolio for Materials Science Research

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker today announced that it has acquired Nion, a privately-held company that develops and manufactures innovative high-end scanning transmission electron microscopes (STEM). Nion was the first company to introduce aberration correction for STEM instruments with ultra-high stability for highest resolution images, and Nion is the world leader in ultra-high energy and spatial resolution electron energy-loss spectroscopy (EELS). This acquisition enhances Bruker’s product offerings and technology portfolio in materials science research and provides the technology base for applications in electron diffraction crystallography. In 2023, Nion had approximately $8 million in revenue. Financial details of the transaction were not disclosed.

Located in Kirkland, WA, USA, Nion was founded in 1997 by Dr. Ondrej Krivanek and Dr. Niklas Dellby. Under their leadership, Nion developed into a premier provider for high-end STEMs for researchers in materials science research worldwide.

“We are excited to add the high-end STEM products, the electron microscopy technology, and this new expertise of Nion to Bruker,” said Dr. Frank Burgaezy, the Bruker AXS division president. “Nion has unique products for the most demanding research applications in materials science electron microscopy, and Bruker will offer Nion global market reach as well as collaborations on new developments to enter new applications in electron diffraction crystallography based on Nion electron microscope and Bruker crystallography technologies.”

“With the introduction of aberration correction and ultra-high energy resolution EELS, Nion has revolutionized STEM technology. With our products we have established an excellent reputation among leading scientists around the globe as a provider of high-end STEM products,” added Dr. Ondrej Krivanek, co-founder of Nion. “Our work has given us unique insights into what researchers need. We are very gratified to join Bruker, an internationally esteemed instrumentation company, whose philosophy, culture, and reputation align very closely with our company culture and our research-oriented goals.”

About Nion

Nion is a world-class developer of advanced scanning transmission electron microscopes (the UltraSTEM™ range) and other electron-optical instruments. Since its founding 26 years ago, Nion has been a major force in advancing the state of the art in electron microscopy, in close collaboration with their customers. The company designs and makes state-of-the art cold field emission guns, aberration correctors, monochromators, sample stages, spectrometers, and detectors. This allows the company to ensure that all the components work together seamlessly, and to deliver world-class instruments that answer needs in the real world, in an integrated and easy-to-use manner.

About Bruker Corporation (NASDAQ: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Contacts

Investor:
Justin Ward
Sr. Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Media:
Dr. Heiko Ress
Bruker AXS Director Marketing Communications
T: +(49) 721 50997-0
E: heiko.ress@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Investor:
Justin Ward
Sr. Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Media:
Dr. Heiko Ress
Bruker AXS Director Marketing Communications
T: +(49) 721 50997-0
E: heiko.ress@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026

SAN DIEGO--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced new updates from Bruker Spatial Biology to be showcased at the 2026 American Association for Cancer Research (AACR) Annual Meeting. At AACR, Bruker Spatial Biology will highlight how its high-fidelity spatial platforms—designed to work together—deliver deeper insights into oncology biology and accelerate translational research. At AACR 2026, Bruker Spatial Biology will launch new cross‑platform workflows linking GeoMx...

Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management

MUNICH--(BUSINESS WIRE)--At ESCMID Global 2026, Bruker announces important portfolio enhancements across microbial identification, outbreak analysis, and reflex next‑generation sequencing (NGS) typing. These latest developments underscore Bruker’s continued commitment to advancing integrated, high‑performance solutions that support laboratories in addressing evolving infectious disease challenges. MALDI Biotyper® Workflow and Identification Enhancements To further streamline routine MALDI‑TOF w...

Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026

MUNICH--(BUSINESS WIRE)--At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division (Bruker Corporation, Nasdaq: BRKR) announces the European launch of MyGenius PRO®, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operati...
Back to Newsroom